<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644618</url>
  </required_header>
  <id_info>
    <org_study_id>Union Hospital</org_study_id>
    <nct_id>NCT00644618</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy</brief_title>
  <official_title>Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Versus Gemcitabine Alone in Patients With Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with unresectable locally advanced pancreatic cancer, the combined use of&#xD;
      external-beam radiation therapy (EBRT) and systemic chemotherapy of 5-FU has been widely&#xD;
      recognized as the most effective chemoradiotherapy approach.But most patients succumb to&#xD;
      local recurrence and metastasis after treatment, and the prognosis remains poor On the basis&#xD;
      of the development and superiority of the interstitial brachytherapy and the radiosensitizing&#xD;
      effect of gemcitabine, we performed a clinical study to explore the interaction of improved&#xD;
      I-125 brachytherapy and gemcitabine and compare the regimen to the standard gemcitabine&#xD;
      treatment specifically in patients with non-metastatic, unresectable pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years after the inclusion of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate, clinical benefit response, and safety</measure>
    <time_frame>2 month after the treatment finished</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>125I brachytherapy PLUS gemcitabine</intervention_name>
    <description>125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven&#xD;
&#xD;
          -  locally advanced pancreatic adenocarcinoma stage&#xD;
&#xD;
          -  No systemic metastases&#xD;
&#xD;
          -  Age between 18-75&#xD;
&#xD;
          -  Karnofsky-Performance Status equal to, or greater than 70 %&#xD;
&#xD;
          -  At least a 2-dimensionally measurable tumor lesion&#xD;
&#xD;
          -  Adequate renal and liver function&#xD;
&#xD;
          -  Written consent statement&#xD;
&#xD;
          -  Patients' compliance and geographical proximity&#xD;
&#xD;
          -  Life expectancy equal to or greater than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious psychological disease&#xD;
&#xD;
          -  Pregnancy and inadequate or not secure contraception or breastfeeding women&#xD;
&#xD;
          -  Other previous malignant disease in the past two years&#xD;
&#xD;
          -  Serious systemic concomitant diseases, excluding participation in a trial&#xD;
&#xD;
          -  Other experimental treatment during or within 6 weeks prior to this trial (including&#xD;
             chemotherapeutic medicine or immune-therapies)&#xD;
&#xD;
          -  Every other condition or therapy assessed by the physician as an eventual risk for the&#xD;
             patient or restricting the aims of the trial&#xD;
&#xD;
          -  Distant metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 24, 2008</last_update_submitted>
  <last_update_submitted_qc>March 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>President Hu Yu</name_title>
    <organization>Union hospital, Huazhong University of Science and Technology</organization>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

